A H5N1 vaccine is an influenza vaccine intended to provide immunization to influenza A virus subtype H5N1. Vaccination of poultry against the avian H5N1 influenza epizootic is widespread in certain countries.

The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is the first adjuvanted influenza vaccine approved by FDA and is for use in people 18 years of age and older...

Jan 2, 2025 · What about an mRNA vaccine for H5N1? There isn't one yet, but several companies—including Moderna, Pfizer and GlaxoSmithKline (in collaboration with CureVac)—are working on such a shot.

Mar 28, 2023 · Influenza Virus Vaccine, H5N1 is used to help prevent disease in people who are at risk of coming into contact with infected birds or other sources of the virus. Influenza Virus Vaccine, H5N1 is for use in adults and children who are at least 6 months old.

Jan 22, 2025 · Earlier this month, a person in Louisiana died after being hospitalized with severe bird flu in December. It’s the country’s first recorded death attributed to H5N1. The US has previously...

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is approved for use in persons (6 months and older) at increased risk of exposure to the influenza A virus H5N1 subtype contained...

For active immunization of persons 18 through 64 years of age at increased risk of exposure to the H5N1 influenza virus subtype contained in the vaccine.

May 16, 2024 · Is a vaccine available to prevent human infection with H5N1 viruses? As part of their influenza pandemic preparedness work, some countries have developed and licensed vaccines that could be used for avian influenza viruses, including H5N1.

Jan 8, 2025 · Description for Arepanrix. AREPANRIX (Influenza A [H5N1] Virus Monovalent Vaccine, Adjuvanted) is a sterile injectable emulsion for intramuscular use.The vaccine is supplied as a vial of inactivated, split-virion, A/H5N1 influenza antigen suspension and a vial of AS03 adjuvant emulsion that must be combined prior to administration.

Dec 31, 2024 · Studies have shown the safety and immunogenicity of A (H5N1) vaccines and the need for a two-dose prime–boost approach and use with adjuvants. 5 Work is ongoing to complete candidate vaccines for...